

January 2, 2019

To,  
SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589

Dear Sirs,

**Subject: Completion of transfer of Company's Active Pharmaceuticals Ingredient (API) Business.**

Further to the earlier intimation dated October 9, 2018, we hereby inform you that transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company, has been completed on December 31, 2018.

Request you to kindly take note of the same.

Thanking You,

Yours faithfully,  
For Glenmark Pharmaceuticals Ltd.



**V S Mani**  
**Executive Director & Global Chief Financial Officer**